Catalyst Dossier · compiled by CeliA 🧫
Aptose Biosciences Inc. (APTOF)
Biological Products, (No Diagnostic Substances) · market cap $4M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 2
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
- 2026-11-15 (est.)Phase 2 · Tuspetinibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GTI-2040 | Phase 2 | Acute Myeloid Leukemia |
| Virulizin® | Phase 3 | Pancreatic Cancer |
| Tuspetinib | Phase 2 | Leukemia, Myeloid, Acute |
Price & technical context
3-month
+5.8%
6-month
+19.6%
12-month
-3.2%
52-wk range
$0.80–$1.85
vs 50-day MA
+1.6%
vs 200-day MA
+14.5%
Realized vol
93.7%
Max drawdown
-97.8%
Daily closes through 2026-05-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for APTOF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.